AGENDA AT A GLANCE

DAY 1
DAY 2

Scaling Next-Gen Biologics in DACH

Upstream Process Intensification
Continuous Manufacturing
Single-Use & Facility Strategies
Advances in Downstream Processing
Manufacturing Innovations for Allogeneic and In Vivo Therapies
Industry Roundtables: Future of Biomanufacturing
Smart Factories: The Role of Digitalisation & AI
Key Takeaways
Supply Chain & Logistics
Drink Reception
End of Conference
VIEW DAY 1
VIEW DAY 2

Day 1

11 February 2026

GO TO DAY 2

8:30

Registration & Coffee

Scaling Next-Gen Biologics in DACH

9:00

Opening Keynote: Advancing Personalising vaccines for commercial success – moving towards phase 3

Simone Steiner | CTO, Transgene, Switzerland

9:25

TBC

9:50

Panel Discussion - Future of Biomanufacturing

Moderator

Uwe Buecheler | Independent Advisor & Former Business Unit Head Biopharmaceuticals, Boehringer Ingelheim, Germany

Panelists

Simone Steiner | CTO, Transgene, Switzerland
Thomas Sauer | Head of Microbial Platform, Global CMC Development, Sanofi, Germany
Volker Huppert | Chief Development Officer, Glycostem, Germany

10:40

Networking Break

Continuous/Intensified Manufacturing

11:15

Topic - TBC

Anne Steinkämper, Senior Scientist, Development Biologicals, Boehringer Ingelheim, Germany

11:40

Panel Discussion

Practical Strategies for Implementing Continuous Manufacturing in Facilities

Max Corbett, Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland

12:20

Lunch Break

Advances in Downstream Processing

13:20

Process Development using high throughput technology and modelling approach

Cecile Brocard | Head of Downstream Development, Boehringer Ingelheim, Austria

13:45

Accelerating Biologic Commercialisation

Andrew Kelly | Director, Manufacturing Technology, BMS, Ireland

14:10

Lean, Patient-Centric Analytical Control Strategies for Commercial Biologics

Keith Coleman | Director - CMC Strategy, BMS, Ireland

14:35

TBC

Karoline Bechtold-Peters | Director Science & Technology, Novartis, Switzerland

14:55

Networking Break

15:30

Roundtable Discussions

  • Navigating Global Policy Shifts in Biologics Procurement
Dennis Stelljes | Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing BMS, Switzerland
  • Digital Maturity in Biomanufacturing: Where Are We, really?
  • Biomanufacturing Facility of the Future: Standardized, Flexible, or Both?
  • Sustainable Biomanufacturing: From Pilot to Practice
  • AI & Future Biomanufacturing Facilities Design
Mohamed S. Chtaini | Executive Director – Global Biologics External Collaborations & Manufacturing, Incyte, Switzerland
  • Stainless Vs Disposable
Karoline Bechtold-Peters | Director Science & Technology, Novartis, Switzerland

17:00

Key Takeaways

17:15

END OF DAY 1

Want to Speak at This Event?

Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.

Apply to Speak

Day 2

12 February 2026

GO TO DAY 1

8:30

Registration & Coffee

Upstream Process Intensification

9:00

Implementing Perfusion Systems for High-Density Cell Culture

Gabriella Cotugno | Head of Vector Construction and Development, Nouscom, Italy

9:25

Process Intensification Opportunities, Challenges and Solutions: Product Quality, Harvest and Scale up Considerations for Intensified Processes

Bassem Ben Yahia | Head of Cell Culture Process Sciences, UCB, Belgium

9:50

Reserved for Solution Provider

10:20

Networking Break

Single-Use & Facility Strategies

10:45

Balancing Stainless Steel and Single-Use Systems in Modern Biomanufacturing Facilities

Mohamed S. Chtaini | Executive Director – Global Biologics External Collaborations & Manufacturing, Incyte, Switzerland

11:10

Reserved for Solution Provider

11:35

Smart Decision-taking with Facility Models Regarding Process Fit and Optimisation

Dr. Joachim Bär| Director Cell Culture Development, Boehringer Ingelheim, Germany

12:00

Lunch Break

Manufacturing Innovations for Allogeneic and In Vivo Therapies

13:00

Developing a Next Generation CAR T-cell Therapy

Dr. John Bridgeman | CSO, Immunokey, UK

13:25

Ensuring Genomic Integrity in Therapeutic Genome Editing: Mitigating Off-Target Risks in CGT Development

Dr. Toni Cathomen | Chair & Professor of Cell and Gene Therapy, Director, University Medical Center Freiburg, Germany

13:50

TBC

Arindam Mitra | Director CMC, Leucid Bio, UK

14:15

Networking Break

Smart Factories: The Role of Digitalisation & AI

14:30

Panel Discussion - Perspectives/Value/Expectations of AI on CGT Manufacturing

Moderator

Pilar Redondo | Site Head , Takeda Spain

Panelists

Gabriella Cotugno | Head of Vector Construction and Development, Nouscom, Italy
Dr. Jan Spanholtz | CSO, Glycostem, Germany
Arindam Mitra | CMC Director, Leucid Bio, UK

15:10

Application of Digital Twins in Biologics Development and Manufacturing

Thomas Sauer | Head of Microbial Platform, Global CMC Development, Sanofi, Germany

Supply Chain & Logistics

15:35

Transport Validation & It's Impact on Site Selection & Global Logistics

Marcel van Houten | Director Global Supply Chain, Orchard Therapeutics, Switzerland

16:00

Building Resilient Supply Networks for Biologics Manufacturing

16:30

Chairman’s Closing Rearks

16:30

END OF CONFERENCE

Get Your Ticket
View the 2025 Post-Event Report